VAXCYTE, INC. Shareholders' Equity
VAXCYTE, INC. (PCVX) had Shareholders' Equity of $2.76 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $2.76B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $3.00B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $2.69B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $2.89B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $2.76B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $3.00B 10-Q · filed 2026-08-05 |
| 2025-12-31 | $2.69B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $2.89B 10-Q · filed 2025-11-04 |
| 2025-06-30 | $3.07B 10-Q · filed 2026-08-05 |
| 2025-03-31 | $3.20B 10-Q · filed 2026-08-05 |
| 2024-12-31 | $3.31B 10-Q · filed 2026-08-05 |
| 2024-09-30 | $3.42B 10-Q · filed 2025-11-04 |
| 2024-06-30 | $1.99B 10-Q · filed 2025-11-04 |
| 2024-03-31 | $1.98B 10-Q · filed 2025-11-04 |
| 2023-12-31 | $1.24B 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.40B 10-Q · filed 2024-11-05 |
| 2023-06-30 | $1.43B 10-Q · filed 2024-11-05 |
| 2023-03-31 | $944.77M 10-Q · filed 2024-11-05 |
| 2022-12-31 | $953.61M 10-K · filed 2026-02-24 |
| 2022-09-30 | $359.31M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $366.50M 10-Q · filed 2023-11-06 |
| 2022-03-31 | $359.54M 10-Q · filed 2023-11-06 |
| 2021-12-31 | $284.02M 10-K · filed 2025-02-25 |
| 2021-09-30 | $305.96M 10-Q · filed 2022-11-07 |
| 2021-06-30 | $317.02M 10-Q · filed 2022-11-07 |
| 2021-03-31 | $326.94M 10-Q · filed 2022-11-07 |
| 2020-12-31 | $345.84M 10-K · filed 2024-02-27 |
| 2020-09-30 | $364.07M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $383.21M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$132.97M 10-Q · filed 2021-11-10 |
| 2019-12-31 | -$106.37M 10-K · filed 2023-02-27 |
| 2019-09-30 | -$92.16M 10-Q · filed 2020-11-12 |
| 2019-06-30 | -$81.48M 10-Q · filed 2020-11-12 |
| 2019-03-31 | -$71.11M 10-Q · filed 2020-11-12 |
| 2018-12-31 | -$57.73M 10-K · filed 2022-02-28 |
| 2017-12-31 | -$29.13M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |